MedTrace Logo

Kaletra Sex/Gender Pharmacokinetics (PK) Study

NCT00148759 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2013-12-03

Study results available
· View outcomes & findings →

Summary

The levels of lopinavir achieved in the blood following oral ingestion of standard doses of Kaletra (lopinavir/ritonavir) in HIV-infected men was compared with those achieved in HIV-infected women receiving the same dose of the drug.

Conditions

  • HIV Infections

Interventions

DRUG

LPV/r

LPV/r 800/200 mg once daily

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Emory University

    lead OTHER

Principal Investigators

  • Igho Ofotokun, MD, MSc · Emory University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148759 on ClinicalTrials.gov